Approximately 10% of CIDP patients exhibit autoantibodies against nodal and paranodal proteins, with anti-NF155 antibodies present in 4%–18% of patients and antibodies against CNTN1, CASPR1, and the CNTN1-CASPR1 complex reported in 1%–7% of patients (5). Here, CNTNAP1 is linked to chronic inflammatory demyelinating polyradiculoneuropathy.